500 UNICORN PARK, WOBURN, MA
Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Provides Update Following Type A Meeting with FDA
Announces Type A Meeting Scheduled with FDA
Earnings Release
Annual Report to Security Holders
Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Reg. FD
Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Q1
FY 2024
Q3
Q2
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement
Correspondence